Journal article
Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations
The Journal of clinical investigation, Vol.109(11), pp.1501-1509
06/2002
DOI: 10.1172/JCI0214858
PMCID: PMC150995
PMID: 12045264
Abstract
NF-kappaB essential modifier (NEMO), also known as IKK-gamma, is a member of the I-kappaB kinase complex responsible for phosphorylating I-kappaB, allowing the release and activation of NF-kappaB. Boys with an expressed NEMO mutation have an X-linked syndrome characterized by hypohidrotic ectodermal dysplasia with immune deficiency (HED-ID). The immunophenotype resulting from NEMO mutation is highly variable, with deficits in both T and B cell responses. We evaluated three patients with NEMO mutations (L153R, Q403X, and C417R) and HED-ID who had evidence of defective CD40 signaling. All three patients had normal percentages of peripheral blood NK cells, but impaired NK cell cytotoxic activity. This was not due to a generalized defect in cytotoxicity because antibody-dependent cellular cytotoxicity was intact. This abnormality was partially reversed by in vitro addition of IL-2, which was also able to induce NF-kappaB activation. In one patient with recurrent cytomegalovirus infections, administration of IL-2 partially corrected the NK cell killing deficit. These data suggest that NEMO participates in signaling pathways leading to NK cell cytotoxicity and that IL-2 can activate NF-kappaB and partially overcome the NK cell defect in patients with NEMO mutations.
Details
- Title: Subtitle
- Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations
- Creators
- Jordan S Orange - Division of Immunology, Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115, USAScott R BrodeurAshish JainFrancisco A BonillaLynda C SchneiderRoberto KretschmerSamuel NurkoWendy L RasmussenJulia R KöhlerStephen E GellisBetsy M FergusonJack L StromingerJonathan ZonanaNarayanaswamy RameshZuhair K BallasRaif S Geha
- Resource Type
- Journal article
- Publication Details
- The Journal of clinical investigation, Vol.109(11), pp.1501-1509
- DOI
- 10.1172/JCI0214858
- PMID
- 12045264
- PMCID
- PMC150995
- NLM abbreviation
- J Clin Invest
- ISSN
- 0021-9738
- eISSN
- 1558-8238
- Publisher
- American Society for Clinical Investigation
- Grant note
- AI-31136 / NIAID NIH HHS\nR01 DE011311 / NIDCR NIH HHS\nM01 RR002172 / NCRR NIH HHS\nM01-RR02172 / NCRR NIH HHS\nT32 AI007512 / NIAID NIH HHS\nU19 AI031541 / NIAID NIH HHS\nR01 AI031136 / NIAID NIH HHS\nAI-31541 / NIAID NIH HHS\nAI-07512 / NIAID NIH HHS\nDE-11311 / NIDCR NIH HHS\nP01 AI031541 / NIAID NIH HHS
- Language
- English
- Date published
- 06/2002
- Academic Unit
- Immunology; Internal Medicine
- Record Identifier
- 9984094637602771
Metrics
19 Record Views